A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Conditions

• Obesity
• Overweight

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• Eloralintide — DRUG
  Administered SC.
• Placebo — DRUG
  Administered SC.

Study Details

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or overweight. The study will last about 64 weeks and may include up to 17 visits.

Key Dates

Start date

Feb 5, 2024

Status verified

May 2026

Primary completion

May 30, 2025

Completion

Aug 14, 2025

Study Design

Enrollment

263 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Placebo Comparator: Placebo
  Participants received subcutaneous (SC) injections of eloralintide-matching placebo administered once weekly (QW) for 48 weeks.
• Experimental: 1 mg Eloralintide
  Participants received eloralintide 1 milligram (mg) SC QW for 48 weeks.
• Experimental: 3 mg Eloralintide
  Participants received eloralintide 3 mg SC QW for 48 weeks.
• Experimental: 6 mg Eloralintide
  Participants received eloralintide 6 mg SC QW for 48 weeks.
• Experimental: 9 mg Eloralintide
  Participants received eloralintide 9 mg SC QW for 48 weeks.
• Experimental: 6/9 mg Eloralintide
  Participants received eloralintide 6 mg SC QW for 20 weeks, followed by eloralintide 9 mg SC QW for 28 weeks, for a total treatment duration of 48 weeks.
• Experimental: 3/6/9 mg Eloralintide
  Participants received eloralintide 3 mg SC QW for 4 weeks, followed by eloralintide 6 mg SC QW for 4 weeks, followed by eloralintide 9 mg SC QW for 40 weeks, for a total treatment duration of 48 weeks.

Primary Outcome Measure

Percent Change From Baseline in Body Weight at Week 48 [ Time Frame: Baseline, Week 48 ]

Locations (43)

Related coverage on Hipa.ai

• Eloralintide Phase 2 Trial Shows Up to 20.1% Weight Loss in Obesity/Overweight
  Eloralintide · Jun 24, 2026 · ClinicalTrials.gov

Find similar trials in Chandler, AZ

Related Studies

• Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
  PHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
• Study to Investigate Genetic Causes of Severe Early Childhood Onset Obesity.
  Recruiting · Columbia University · Boston, Massachusetts
• Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
  Recruiting · University of Michigan · Ann Arbor, Michigan
• Investigating the Impact of Obesity on Pubertal Development in Girls
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Research Triangle Park, North Carolina